Consumers are racing to cut out traditional television services, and that's not good news for TV-dependent pharma. But there's a silver lining.
AbbVie is thinking about reneging on its 10% price-hike limit announced in January, executives said in a recent meeting with analysts.
With its latest FDA nod, Bristol-Myers Squibb’s Opdivo won the right to take on Bayer's Stivaga in liver cancer.
Congress has called on Merck CEO Ken Frazier to give full accounting on how badly affected its global manufacturing was by the Petya malware attack.
Steve Miller, CMO of Express Scripts, is not mincing words in his assessment of Kymriah, Novartis' $475,000 CAR-T treatment for leukemia.
Despite lots of value-based talk, a new PwC survey finds the new payer contracting approach has yet to take off in a major way.
Intercept has been the presumed leader in the NASH drug race, but 19 deaths in current Ocaliva patients pose a threat to those plans.
Not all Big Pharma's businesses in emerging markets are doing so well, Fosun is buying a smaller stake in Gland, Taiho and Arcus ink cancer option deal.
Impax Labs CEO Paul Bisaro, who has extensive experience building companies through M&A, is reportedly in talks with competitor Amneal.
Pfizer and Merck KGaA’s Bavencio, which won an FDA nod for Merkel cell carcinoma in March, has now been approved in Europe to treat that cancer.